Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Department of Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Curr Top Behav Neurosci. 2023;62:133-163. doi: 10.1007/7854_2022_305.
Most psychiatric illnesses, such as schizophrenia, show profound sex differences in incidence, clinical presentation, course, and outcome. Fortunately, more recently the literature on sex differences and (to a lesser extent) effects of sex steroid hormones is expanding, and in this review we have focused on such studies in psychosis, both from a clinical/epidemiological and preclinical/animal model perspective. We begin by briefly describing the clinical evidence for sex differences in schizophrenia epidemiology, symptomatology, and pathophysiology. We then detail sex differences and sex hormone effects in behavioral animal models of psychosis, specifically psychotropic drug-induced locomotor hyperactivity and disruption of prepulse inhibition. We expand on the preclinical data to include developmental and genetic models of psychosis, such as the maternal immune activation model and neuregulin transgenic animals, respectively. Finally, we suggest several recommendations for future studies, in order to facilitate a better understanding of sex differences in the development of psychosis.
大多数精神疾病,如精神分裂症,在发病率、临床表现、病程和预后方面存在明显的性别差异。幸运的是,最近关于性别差异以及(在较小程度上)性激素影响的文献正在不断增加,在这篇综述中,我们主要关注了精神疾病领域中的这些研究,包括从临床/流行病学和临床前/动物模型的角度。我们首先简要描述了精神分裂症流行病学、症状学和病理生理学方面的性别差异的临床证据。然后,我们详细介绍了精神分裂症动物行为模型中的性别差异和性激素作用,特别是精神药物引起的运动过度和前脉冲抑制破坏。我们将临床前数据扩展到包括精神分裂症的发育和遗传模型,分别是母体免疫激活模型和神经调节素转基因动物。最后,我们提出了一些未来研究的建议,以促进更好地理解精神分裂症发展过程中的性别差异。